- Joined
- Aug 9, 2013
- Messages
- 102
- Reaction score
- 1
Hi guys!
I'm a dental student, and I'm strongly interested in specializing in academic oral-maxillofacial surgical oncology. I enjoy keeping myself informed on recent advances in related fields, such as interventional oncology and nuclear medicine.
I read about the success Zevalin and Bexxar have had in converting partial responses to R-CHOP in NHL to complete ones, at a low rate of ADRs, so I'm very interested in RIT.
I just got done reading these two very interesting articles:
1. Ophthalmic artery chemosurgery for retinoblastoma:http://www.retinalphysici....aspx?articleID=107657
2. Alpha radioimmunotherapy for radio- and chemoresistant NHL:
http://www.ncbi.nlm.nih.g..mc/articles/PMC3712568/
So, I have an interesting theory on how to treat tongue SCC:
1. Perform dosimetric calculations to determine the activity of Bi-213 needed to deliver an 80Sv dose to the tumor.
2. Conjugate anti-SCCA mAbs to Bi-213.
3. Do a selective lingual angiogram to determine the tumor vascular anatomy.
4. Inject the mAb conjugate into the tumor feeder arteries.
5. Do PET scan 1 day post-op to determine if the alpha radiation has rendered the tumor metabolically inactive.
The lingual artery catheterization will ensure the therapy will be localized to the tongue, and the SCCA mAbs will ensure the radionuclide will only be delivered to the SCC cells.
I strongly believe that this "superselective intra-arterial immunotargeted alpha radiosurgery" would be a very effective treatment for H&N tumors, as
1. Alpha radiation does not require free radical generation to damage DNA due to its high LET.
2. The short penetration length minimizes damage to nearby healthy cells.
3. Alpha radiation can damage the leaky endothelium within the tumor's circulation. http://medicalphysicsweb.org/cws/article/research/30589
The best mAb to load Bi-213 on would be one that is bispecific for SCCA and a pericyte antigen.
This seems like a promising treatment idea. I wonder if anyone has tried irreversible electroporation in oral cancer.
Interventional oncology seems to be limited in the field of H&N to performing pre-op tumor embolization; I wonder why?
Thanks!
I'm a dental student, and I'm strongly interested in specializing in academic oral-maxillofacial surgical oncology. I enjoy keeping myself informed on recent advances in related fields, such as interventional oncology and nuclear medicine.
I read about the success Zevalin and Bexxar have had in converting partial responses to R-CHOP in NHL to complete ones, at a low rate of ADRs, so I'm very interested in RIT.
I just got done reading these two very interesting articles:
1. Ophthalmic artery chemosurgery for retinoblastoma:http://www.retinalphysici....aspx?articleID=107657
2. Alpha radioimmunotherapy for radio- and chemoresistant NHL:
http://www.ncbi.nlm.nih.g..mc/articles/PMC3712568/
So, I have an interesting theory on how to treat tongue SCC:
1. Perform dosimetric calculations to determine the activity of Bi-213 needed to deliver an 80Sv dose to the tumor.
2. Conjugate anti-SCCA mAbs to Bi-213.
3. Do a selective lingual angiogram to determine the tumor vascular anatomy.
4. Inject the mAb conjugate into the tumor feeder arteries.
5. Do PET scan 1 day post-op to determine if the alpha radiation has rendered the tumor metabolically inactive.
The lingual artery catheterization will ensure the therapy will be localized to the tongue, and the SCCA mAbs will ensure the radionuclide will only be delivered to the SCC cells.
I strongly believe that this "superselective intra-arterial immunotargeted alpha radiosurgery" would be a very effective treatment for H&N tumors, as
1. Alpha radiation does not require free radical generation to damage DNA due to its high LET.
2. The short penetration length minimizes damage to nearby healthy cells.
3. Alpha radiation can damage the leaky endothelium within the tumor's circulation. http://medicalphysicsweb.org/cws/article/research/30589
The best mAb to load Bi-213 on would be one that is bispecific for SCCA and a pericyte antigen.
This seems like a promising treatment idea. I wonder if anyone has tried irreversible electroporation in oral cancer.
Interventional oncology seems to be limited in the field of H&N to performing pre-op tumor embolization; I wonder why?
Thanks!